Testing effectiveness (Phase 2)UnknownNCT00979160What this trial is testingEvaluation of Response of Dasatinib to Treat MastocytosisWho this might be right forSystemic Mastocytosis Federico II University 30
Testing effectiveness (Phase 2)Study completedNCT00171912What this trial is testingImatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase EnzymesWho this might be right forHypereosinophilic SyndromeSystemic MastocytosisChronic Myelomonocytic Leukemia+1 more Novartis Pharmaceuticals 38
Not applicableStudy completedNCT00890435What this trial is testingDecision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical TrialWho this might be right forBrain and Central Nervous System TumorsLeukemiaUnspecified Adult Solid Tumor, Protocol Specific+1 more Children's Oncology Group 53
Not applicableUnknownNCT06013683What this trial is testingA Registry for Patients With Systemic Mastocytosis in ChinaWho this might be right forSystemic Mastocytoses The First Affiliated Hospital of Soochow University 150
Not applicableStudy completedNCT00898079What this trial is testingCollecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With CancerWho this might be right forAcute Undifferentiated LeukemiaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeChildhood Acute Lymphoblastic Leukemia+11 more Children's Oncology Group 2,545
Large-scale testing (Phase 3)UnknownNCT04333108What this trial is testingMasitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic TreatmentWho this might be right forIndolent Systemic Mastocytosis AB Science 140
Not applicableEnded earlyNCT00726830What this trial is testingMethadone, Morphine, or Oxycodone in Treating Pain in Patients With CancerWho this might be right forBrain and Central Nervous System TumorsChronic Myeloproliferative DisordersLeukemia+8 more M.D. Anderson Cancer Center 1
Large-scale testing (Phase 3)Study completedNCT03401060What this trial is testingInterest of Denosumab Treatment in Osteoporosis Associated to Systemic MastocytosisWho this might be right forOsteoporosisSystemic Mastocytosis Assistance Publique - Hôpitaux de Paris 24
Testing effectiveness (Phase 2)Study completedNCT00782067What this trial is testingEfficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell LeukemiaWho this might be right forLeukemia Novartis Pharmaceuticals 116
Testing effectiveness (Phase 2)Study completedNCT00449748What this trial is testingEverolimus (RAD001) as Therapy for Patients With Systemic MastocytosisWho this might be right forSystemic Mastocytosis M.D. Anderson Cancer Center 10
Not applicableWithdrawnNCT00499668What this trial is testingAprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With CancerWho this might be right forMyeloproliferative DisordersLeukemiaLymphoma+5 more Vanderbilt-Ingram Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00627666What this trial is testingDonor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological CancerWho this might be right forLeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms Asan Medical Center 52
Early research (Phase 1)Study completedNCT02561988What this trial is testing(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid MalignanciesWho this might be right forAggressive Systemic MastocytosisSystemic Mastocytosis-associated Hematologic Non-mast Cell DiseaseMast Cell Leukemia+1 more Blueprint Medicines Corporation 86
Testing effectiveness (Phase 2)Study completedNCT00233454What this trial is testingPhase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell LeukemiaWho this might be right forSystemic Mastocytosis, Aggressive (ASM)Leukemia, Mast CellHematological Non-mast Cell Lineage Disease (AHNMD) Jason Robert Gotlib 26
Early research (Phase 1)Study completedNCT02808793What this trial is testingEvaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002Who this might be right forIndolent Systemic Mastocytosis Allakos Inc. 25
Not applicableStudy completedNCT00769587What this trial is testingThalidomide in Treating Patients With Relapsed or Progressive Systemic MastocytosisWho this might be right forNon Neoplastic ConditionPrecancerous Condition Centre Hospitalier Universitaire, Amiens
Testing effectiveness (Phase 2)Ended earlyNCT00918931What this trial is testingObatoclax for Systemic MastocytosisWho this might be right forLeukemiaSystemic Mastocytosis M.D. Anderson Cancer Center 3
Testing effectiveness (Phase 2)Study completedNCT02478957What this trial is testingTreatment of Indolent Systemic Mastocytosis With PA101Who this might be right forMastocytosisSystemic MastocytosisIndolent Systemic Mastocytosis Patara Pharma 41
Early research (Phase 1)Study completedNCT04681105What this trial is testingFlotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological MalignanciesWho this might be right forRecurrent Acute LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent Blastic Plasmacytoid Dendritic Cell Neoplasm+14 more City of Hope Medical Center 13
Early research (Phase 1)Study completedNCT01231919What this trial is testingMK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaWho this might be right forAccelerated Phase Chronic Myelogenous LeukemiaAcute Leukemias of Ambiguous LineageAcute Myeloid Leukemia/Transient Myeloproliferative Disorder+48 more National Cancer Institute (NCI) 45